Latest Kaiser Health News Stories
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try — once again — to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.
The U.S. Preventive Services Task Force recommended that people who are at high risk of contracting HIV take PrEP, a preventive treatment. The decision means most health plans will be required to cover the drugs without charging patients. But the recommendation doesn’t apply to the other clinical and lab services people need.
KHN, in collaboration with PBS NewsHour, reports on the skyrocketing cost of insulin — and the trend’s deadly consequences. The price in the U.S. nearly doubled from 2012 to 2016, prompting some patients and activists to travel to Canada, where insulin can be 90% cheaper.
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Colorado, Florida and Vermont — with the support of President Donald Trump — are exploring plans to bring drugs across the border from Canada to help lower costs.
Independent black-owned pharmacies fill a void for African American patients looking for care that’s sensitive to their heritage, beliefs and values.
Beware at the pharmacy counter: Your insurance company could be in cahoots with a pharmacy benefit manager — and the negotiations that go on between them are trade secrets.
Guess who’s back grabbing headlines? Pharmacy benefit managers — those companies that serve as middlemen in the prescription drug pipeline.
Julie Rovner, the chief Washington correspondent for Kaiser Health News, joins Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Alan Weil of Health Affairs at the Aspen Ideas: Health festival to discuss how consumers’ values impact the politics surrounding the national debate on health care.
A new data analysis by KHN and Johns Hopkins researchers shows that even as the CDC issued warnings, surgeons handed out many times the number of opioid pills needed for post-op pain.
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
For the seventh year in a row, Missouri will retain its lonely title as the only state without a statewide prescription drug monitoring program. Fears about privacy violations and gun control scuttled the bill yet again, leaving a pastiche of half-step measures in place to fill the void in the fight against prescription drug abuse.